Latest Market Impact News

WhiteHawk Limited and DoxAI have forged a three-year strategic partnership to integrate AI-driven automation with advanced cyber risk and compliance solutions, aiming to accelerate digital transformation across key sectors in North America and Australia.

The Supreme Court of New South Wales has approved the merger of Brickworks Limited and Washington H. Soul Pattinson, paving the way for a new ASX-listed entity, First Services Company Ltd. Shareholders will soon exchange their Brickworks shares for Topco shares as trading transitions next week.

Altech Batteries has announced breakthrough performance milestones for its CERENERGY sodium nickel chloride battery technology, demonstrating exceptional cycle life, efficiency, and safety that position it as a strong contender in grid and industrial energy storage.

Shareholders of Washington H. Soul Pattinson and Brickworks have overwhelmingly approved their respective share schemes, paving the way for a major merger and new leadership incentives.

Catalyst Metals Limited will enter the S&P/ASX 200 Index on 16 September 2025, marking a significant milestone as it replaces Brickworks Limited. The move highlights Catalyst’s growing gold resource base and production plans in Western Australia.

Morella Corporation has restructured its joint venture with Lithium Corporation, gaining 100% ownership of key Nevada lithium assets and streamlining its exploration portfolio.

McLaren Minerals reports continued high-grade assay results confirming a significant northern extension to its McLaren Titanium Project resource, underpinning an upcoming resource upgrade and prefeasibility study.

Woolworths Group has confirmed its full-year earnings for 2025 met market expectations, responding comprehensively to ASX inquiries about potential material variances. The retailer’s underlying results closely matched analyst consensus, despite statutory impairments and restructuring costs.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Pathkey.AI’s TrialKey platform has demonstrated a 73% alignment with actual biotech trial outcomes, showing an average hypothetical share price gain of 76%, underscoring AI’s growing role in clinical trial prediction and biotech investing.

iTech Minerals has responded to ASX concerns, confirming it disclosed material information on its Bayonet, Sabre, and Falchion prospects promptly and in compliance with listing rules.

Cavalier Resources has raised $2.14 million through a discounted placement to fast-track drilling at its Crawford Gold Project, while continuing negotiations for a $11 million pre-payment deal.